2658-6533Research Results in Biomedicine2658-653310.18413 / 2313-8955-2014-1-1-5-11224Archive categoriesCOMPARATIVE ANALYSIS OF OMACOR AND SIMVASTATIN CLINICAL EFFECTIVENESS IN CORRECTION OF HYPERLIPIDEMIA IN CHD PATIENTS WITH POSTINFARCTION CARDIOSCLEROSIS AND DISORDERS OF RHYTHMCOMPARATIVE ANALYSIS OF OMACOR AND SIMVASTATIN CLINICAL EFFECTIVENESS IN CORRECTION OF HYPERLIPIDEMIA IN CHD PATIENTS WITH POSTINFARCTION CARDIOSCLEROSIS AND DISORDERS OF RHYTHMMalGalina S.MalGalina S.mgalina.2013@mail.ru20141100

The article is dedicated to the study of drugs which possess antiarrhythmic effects and normalize lipid exchange in prevention of atherosclerosis as the cause of coronary heart disease. Some of these drugs are ω3 polyunsaturated fatty acids (omacor). As a result of conducted researches, in the correction of IIB and IV types of hyperlipidemia with simvastatin and omacor, the author discovers a significant degree of manifestation of hypotriglyceridemic effects of drugs, which is consistent with the previous studies. The 24 weeks pharmacotherapy with ω-3 polyunsaturated fatty acids in patients with coronary heart disease and different types of arrhythmia resulted in the decrease in the number of ventricular and supraventricular ekstrasystols, thus, proving the possibility of using ω-3 polyunsaturated fatty acids in patients with coronary heart disease and postinfarction cardiosclerosis associated with clinically significant arrhythmia. The ability of omacor to demonstrate a significant hypotriglyceridemic effect, as well as its ability to exercise antiarrhythmic effect on the severity of ventricular and supraventricular premature beats make its use sensible and pharmacoeconomically justified.

The article is dedicated to the study of drugs which possess antiarrhythmic effects and normalize lipid exchange in prevention of atherosclerosis as the cause of coronary heart disease. Some of these drugs are ω3 polyunsaturated fatty acids (omacor). As a result of conducted researches, in the correction of IIB and IV types of hyperlipidemia with simvastatin and omacor, the author discovers a significant degree of manifestation of hypotriglyceridemic effects of drugs, which is consistent with the previous studies. The 24 weeks pharmacotherapy with ω-3 polyunsaturated fatty acids in patients with coronary heart disease and different types of arrhythmia resulted in the decrease in the number of ventricular and supraventricular ekstrasystols, thus, proving the possibility of using ω-3 polyunsaturated fatty acids in patients with coronary heart disease and postinfarction cardiosclerosis associated with clinically significant arrhythmia. The ability of omacor to demonstrate a significant hypotriglyceridemic effect, as well as its ability to exercise antiarrhythmic effect on the severity of ventricular and supraventricular premature beats make its use sensible and pharmacoeconomically justified.

omacorantiarrhythmic effectω-3 polyunsaturated fatty acidsomacorantiarrhythmic effectω-3 polyunsaturated fatty acidsСписок литературы1.  Bibikova, M.V. Perspektivy i primenenie statinov / Bibikova M.V. // Farm. vest. [Perspectives and Use of Statins / Bibikova M.V. // Pharm. Bulletin], 2003. №4. 30 p.2.  Vasil'eva A.D. Omega-3 polinenasyshchennye zhirnye kisloty v profilaktike i lechenii ateroskleroza // Russkiy Meditsinskiy Zhurnal [Omega-3 Polyunsaturated Fatty Acids in Prophylaxis ant Treatment of Atheriosclerosis // Russian Medical Journal], 2007. №9. pp. 752-757.3.  Vserossiyskoe nauchnoe obshchestvo kardiologov. Diagnostika i korrektsiya narusheniy lipidnogo obmena s tsel'yu profilaktiki i lecheniya ateroskleroza [Society of Cardiology of the Russian Federation. Diagnostics and Correction of Lipid Exchange Disorders in Prevention and Treatment of Atherosclerosis]. M., 2004. 17 p.4.  Ievleva, A.Ya. Preventivnaya farmakoterapiya koronarnoy bolezni serdtsa [Preventive Pharmacotherapy of Coronary Heart Disease]. - M.: Meditsina, 1998. pp. 15-18.5.  Kalashnikov, V.Yu. Provedenie kliniko-ekonomicheskikh issledovaniy: neobkhodimost' ili dan' mode // Kachestven.klinich. praktika [Clinico-Economic Studies: Necessity or Tribute to Fashion // Quality Clinical Practice], 2004. №1. pp. 34-38.6.  Martynov  A.I.   Novye  dokazatel'stva  vozmozhnosti  primeneniya omega-3 kislot s tsel'yu vtorichnoy profilaktiki infarkta miokarda / A.I. Martynov, V.L. Khomenko // Ratsional'naya Farmakoterapiya v Kardiologii [New Evidence of the Use of Omega-3 Acids in secondary Prophylaxis of  Myocardial Infarction // Rational Pharmacotherapy in Cardiology], 2006. №3.7.  Nifontov E.M., Shikhaliev D.R., Bogachev M.I., Krasichkov A.S., Shlyakhto E.V. Antiaritmicheskaya effektivnost' omega-3 polinenasyshchennykh zhirnykh kislot u bol'nykh stabil'noy ishemicheskoy bolezn'yu serdtsa s zheludochkovymi narusheniyami ritma // Kardiologiya [Antiarrhythmic Effeciency of Omega-3 Fatty Acids in Patients with Stable Coronary Heart disease and Ventricular Arrhythmia // Cardiology], 2010. №12. pp.4-9.8.  Polonskiy, V.M. Novye dannye o statinakh / V.M.Polonskiy // Farmateka [New Information about Statins // Pharmateka]. 2001. №1. pp. 40-41.9.  Balk EM, Lichtenstein AH, Chung M et al. Effects of Omega-3 Fatty Acids on Serum Markers of Cardiovascular Disease Risk: A Systematic Review. Atherosclerosis, 2006. 189 (1):19-30.10.           Carney RM, Freedland KE, Rubin EH, et al. Omega-3 Augmentation of Sertraline in Treatment of Depression in Patients with Coronary Heart Disease; a Randomized Controlled Trial. URL: JAMA, 2009;302:1651-7.11.           Dietary Supplementation with n-3 Polyunsaturated Fatty Acids and Vitamin E after Myocardial Infarction: Results of the GISSI-Prevenzione Trial: GruppoItaliano per lo Studio della Sopravvivenzanell’ Infartomiocardico. Lancet, 1999. 354: 447-455.12.           Siscovic D.S., Lemaitre R.N., Mozaffarian D. The Fish Story: a Diet-Heart Hypothesis with Clinical Implications: n-3 Polyunsaturated Fatty Acids, Myocardial Vulnerability, and Sudden Death. Circulation, 2003. Vol. 107. pp. 2632-2634.13.           Skeaff C.M., Miller J. Dietary Fat and Coronary Heart Disease: Summary of Evidence from Prospective Cohort and Randomized Controlled Trials // Ann Nutr Metab, 2009. Vol. 55. pp. 177-20114.           Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K. Effects of Eicosapentaenoic Acid on Major Coronary Events in Hypercholesterolaemic Patients (JELIS): a Randomised Open-label, Blinded Endpoint Analysis. Lancet, 2007; 369: 1090-1098.